Clear Street raised the firm’s price target on Krystal Biotech (KRYS) to $217 from $212 and keeps a Buy rating on the shares after Krystal reported Q3 results. The firm, which see Vyjuvek as having steadied in the U.S. and near term growth to be driven by international launches, increased its FY25 revenue estimate to $383M and decreased its expense estimates in line with guidance.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KRYS:
- Krystal Biotech sees FY25 non-GAAP R&D, SG&A expense $145M-$155M
- Krystal Biotech reports Q3 EPS $2.66, consensus $1.12
- KRYS Earnings this Week: How Will it Perform?
- Krystal Biotech’s Promising Lung Cancer Study: A Potential Game-Changer?
- Krystal Biotech’s KB407 Study: A Promising Step for Cystic Fibrosis Treatment